The Use of the Prostaglandin Synthetase Inhibitor Mefenamic Acid in the Treatment of Menorrhagia

Diana Jakubowicz, Carl Wood
In: Australian and New Zealand Journal of Obstetrics and Gynaecology · 1978 · vol. 18(2) , pp. 135–138 · doi:10.1111/j.1479-828x.1978.tb00031.x · W1996069690
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Mefenamic acid significantly reduced menstrual blood loss in women with menorrhagia compared to placebo with minimal side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Summary: A randomized, controlled, double‐blind clinical trial was conducted to compare the effect of the prostaglandin synthetase inhibitor mefenamic acid (Ponstan) given during menstruation to that of a placebo in the treatment of menorrhagia. A statistically significant reduction in menstrual blood loss was recorded by 14 of 15 patients in the mefenamic acid group. The incidence of side effects was minimal. Placebo therapy was significantly more effective than no therapy. Further exploration of the use of mefenamic acid in patients with excessive menstrual loss is recommended.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

Cited by (4)

References (11)

Cited by (4)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-09-16T06:28:21.314993+00:00
License: CC0 · commercial use OK